Description
This measure details the prevalence of identified gout in those enrolled with primary health organisations. Rates of gout are particularly high in Māori and Pacific males, meaning districts with a high Māori and/or Pacific population have higher prevalence.
Measure set
Notes about this measure set
Numerator
Those aged 20 years and over identified with gout using the HealthTracker method- (discharge diagnosis of gout (ICD 9 274, ICD 10 M10) from a public hospital admission from 1 January 1988 to 31 December 2019 or who were dispensed gout-specific urate-lowering therapy (allopurinol, febuxostat or benzbromarone) or colchicine from a community pharmacy between 2001 and 2019.
Denominator
Stats NZ population aged 20 years and over, using Stats NZ population projections for the relevant years.
Denominator exclusions
- Patients with a diagnosis of leukaemia or lymphoma (ICD 10 C81–C96).
- The year of dispensing is the same as or after the year of death.
- The patient category is either J or Y (juvenile or youth).
- Dispensings of allopurinol or febuxostat are excluded as indications of gout if there is a diagnosis of malignant neoplasm of lymphoid, haematopoietic and related tissues (ICD-10- AM C81–C96) recorded in either the New Zealand Cancer Registry or in the publicly funded hospitalisations in the NMDS in the 24 months before the period end date.
Responsible organisation(s)
Data sources
Resources
Measure Technical Document: Gout Prevalence (.pdf)
Resource Type
Description
This document contains a detailed definition of the measure.